A preclinical overview of emerging therapeutic targets for glomerular diseases

ABSTRACT Introduction: Animal models have provided significant insights into the mechanisms responsible for the development of glomerular lesions and proteinuria; they have also helped to identify molecules that control the podocyte function as suitable target-specific therapeutics. Areas covered: We discuss putative therapeutic targets for proteinuric glomerular diseases. An exhaustive search for eligible studies was performed in PubMed/MEDLINE. Most of the selected reports were published in the last decade, but we did not exclude older relevant milestone publications. We consider the molecules that regulate podocyte cytoskeletal dynamics and the transcription factors that regulate the expression of slit-diaphragm proteins. There is a focus on SGLT2 and sirtuins which have recently emerged as mediators of podocyte injury and repair. We also examine paracrine signallings involved in the cross-talk of injured podocytes with the neighbouring glomerular endothelial cells and parietal epithelial cells. Expert opinion: There is a need to discover novel therapeutic moleecules with renoprotective effects for those patients with glomerular diseases who do not respond completely to standard therapy. Emerging strategies targeting components of the podocyte cytoskeleton or signallings that regulate cellular communication within the glomerulus are promising avenues for treating glomerular diseases.

[1]  Jian Cai,et al.  uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. , 2019, The Journal of clinical investigation.

[2]  S. Dryer,et al.  TRPC channels: Regulation, dysregulation and contributions to chronic kidney disease. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[3]  J. Heymann,et al.  c-Src is in the effector pathway linking uPAR and podocyte injury. , 2019, The Journal of clinical investigation.

[4]  S. Alper,et al.  Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity , 2019, Proceedings of the National Academy of Sciences.

[5]  K. Tuttle,et al.  Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease , 2019, Diabetes.

[6]  J. Reiser,et al.  More expression, less function: cleaved dynamin in glomerular kidney disease , 2018, The Journal of pathology.

[7]  H. Spaink,et al.  Increased dynamin expression precedes proteinuria in glomerular disease , 2018, The Journal of pathology.

[8]  A. Pini,et al.  Inhibiting the urokinase‐type plasminogen activator receptor system recovers STZ‐induced diabetic nephropathy , 2018, Journal of cellular and molecular medicine.

[9]  H. Anders,et al.  CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism , 2018, Kidney international.

[10]  Changhong Qiao,et al.  CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[11]  Edward Y. Chen,et al.  Podocyte-Specific Induction of Krüppel-Like Factor 15 Restores Differentiation Markers and Attenuates Kidney Injury in Proteinuric Kidney Disease. , 2018, Journal of the American Society of Nephrology : JASN.

[12]  G. Remuzzi,et al.  SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. , 2018, JCI insight.

[13]  J. Wetzels,et al.  The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury. , 2018, Journal of the American Society of Nephrology : JASN.

[14]  V. D’Agati,et al.  Krüppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation. , 2018, JCI insight.

[15]  M. Saleem What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease? , 2018, Nephron.

[16]  Y. Kim,et al.  Loss of KLF15 accelerates chronic podocyte injury. , 2018, International journal of molecular medicine.

[17]  Kyung Lee,et al.  Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. , 2018, Kidney international.

[18]  A. Benigni,et al.  Sirtuins in Renal Health and Disease. , 2018, Journal of the American Society of Nephrology : JASN.

[19]  S. S. Hall Omen in the blood. , 2018, Science.

[20]  P. Scambler,et al.  Activation of podocyte Notch mediates early Wt1 glomerulopathy , 2018, Kidney international.

[21]  A. Advani,et al.  Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. , 2018, American journal of physiology. Renal physiology.

[22]  R. Bindels,et al.  Renal physiology: TRPC5 inhibition to treat progressive kidney disease , 2018, Nature Reviews Nephrology.

[23]  Xuexiang Wang,et al.  TRPC5 Does Not Cause or Aggravate Glomerular Disease. , 2017, Journal of the American Society of Nephrology : JASN.

[24]  M. Saleem Saleem, M. A. (2018). What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease? Nephron, , 2018 .

[25]  E. Lander,et al.  A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models , 2017, Science.

[26]  G. Remuzzi,et al.  The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. , 2017, The American journal of pathology.

[27]  T. B. Huber,et al.  The Evolving Complexity of the Podocyte Cytoskeleton. , 2017, Journal of the American Society of Nephrology : JASN.

[28]  G. Remuzzi,et al.  Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function , 2017, Nature Communications.

[29]  Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling , 2017, Nature Communications.

[30]  J. Lovshin,et al.  Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? , 2017, Current opinion in nephrology and hypertension.

[31]  T. Uzu,et al.  O‐linked &bgr;‐N‐acetylglucosamine modification of proteins is essential for foot process maturation and survival in podocytes , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  A. Azab,et al.  CXCL12 and CXCR7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma , 2017, British journal of haematology.

[33]  J. Coresh,et al.  A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease , 2017, Nature Medicine.

[34]  Benjamin S. Freedman,et al.  Can podocytes be regenerated in adults? , 2017, Current opinion in nephrology and hypertension.

[35]  F. Grahammer,et al.  The long journey through renal filtration: new pieces in the puzzle of slit diaphragm architecture , 2017, Current opinion in nephrology and hypertension.

[36]  P. Zhang,et al.  SIRT3-KLF15 signaling ameliorates kidney injury induced by hypertension , 2017, Oncotarget.

[37]  N. Perico,et al.  ACE and SGLT2 inhibitors: the future for non‐diabetic and diabetic proteinuric renal disease , 2017, Current opinion in pharmacology.

[38]  Patrick D. Dummer,et al.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice , 2017, Nature Medicine.

[39]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[40]  H. Anders,et al.  Sodium glucose transporter‐2 inhibition has no renoprotective effects on non‐diabetic chronic kidney disease , 2017, Physiological reports.

[41]  R. Tilton,et al.  Sirt6 deficiency results in progression of glomerular injury in the kidney , 2017, Aging.

[42]  J. He,et al.  The critical role of Krüppel-like factors in kidney disease. , 2017, American journal of physiology. Renal physiology.

[43]  D. Scadden,et al.  Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease , 2016, Nature Medicine.

[44]  K. Asanuma,et al.  The role of Notch signaling in kidney podocytes , 2017, Clinical and Experimental Nephrology.

[45]  F. Hildebrandt,et al.  Genetic testing in steroid-resistant nephrotic syndrome: when and how? , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  G. Remuzzi,et al.  Podocyte–actin dynamics in health and disease , 2016, Nature Reviews Nephrology.

[47]  A. Benigni,et al.  Clinical Practice : Mini-Review , 2016 .

[48]  G. Remuzzi,et al.  A previously unrecognized role of C3a in proteinuric progressive nephropathy , 2016, Scientific Reports.

[49]  G. Remuzzi,et al.  Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. , 2016, Pharmacological research.

[50]  M. Nagata,et al.  Podocyte injury and its consequences. , 2016, Kidney international.

[51]  V. D’Agati,et al.  G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. , 2016, Journal of the American Society of Nephrology : JASN.

[52]  G. Remuzzi,et al.  Progression, Remission and Regression of Chronic Renal Diseases , 2016, Nephron.

[53]  R. Lennon,et al.  Glomerular cell crosstalk , 2016, Current opinion in nephrology and hypertension.

[54]  R. Preissner,et al.  TRPC6 G757D Loss-of-Function Mutation Associates with FSGS. , 2016, Journal of the American Society of Nephrology : JASN.

[55]  M. Jeansson,et al.  Vascular Growth Factors and Glomerular Disease. , 2016, Annual review of physiology.

[56]  K. Thai,et al.  Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease , 2016, PloS one.

[57]  Chrysta C. Meadowbrooke,et al.  Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective. , 2015, Journal of the American Society of Nephrology : JASN.

[58]  A. Quyyumi,et al.  Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.

[59]  J. Kopp Replenishment of the podocyte compartment by parietal epithelial cells. , 2015, Kidney international.

[60]  Nicolas Wieder,et al.  Calcium, TRPC channels, and regulation of the actin cytoskeleton in podocytes: towards a future of targeted therapies , 2015, Pediatric Nephrology.

[61]  M. Nangaku,et al.  Sirtuin1 Maintains Actin Cytoskeleton by Deacetylation of Cortactin in Injured Podocytes. , 2015, Journal of the American Society of Nephrology : JASN.

[62]  A. Buccoliero,et al.  Podocyte Regeneration Driven by Renal Progenitors Determines Glomerular Disease Remission and Can Be Pharmacologically Enhanced , 2015, Stem cell reports.

[63]  C. Chatziantoniou,et al.  Activation of Notch3 in Glomeruli Promotes the Development of Rapidly Progressive Renal Disease. , 2015, Journal of the American Society of Nephrology : JASN.

[64]  S. Shankland,et al.  Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis , 2015, Kidney international.

[65]  M. Selig,et al.  Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models , 2015, Nature Medicine.

[66]  G. Remuzzi,et al.  Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. , 2015, Journal of Clinical Investigation.

[67]  L. Cai,et al.  Sirtuin 1: A Target for Kidney Diseases , 2015, Molecular medicine.

[68]  J. He,et al.  JAK inhibition and progressive kidney disease , 2015, Current opinion in nephrology and hypertension.

[69]  T. Nakagawa,et al.  Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease. , 2014, American journal of physiology. Renal physiology.

[70]  M. Sarwal,et al.  A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation , 2014, Science Translational Medicine.

[71]  M. Ploug,et al.  Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. , 2014, Journal of the American Society of Nephrology : JASN.

[72]  B. Hyman,et al.  Regulation of Dynamin Oligomerization in Cells: The Role of Dynamin–Actin Interactions and Its GTPase Activity , 2014, Traffic.

[73]  H. Sasamura,et al.  KLF4-dependent epigenetic remodeling modulates podocyte phenotypes and attenuates proteinuria. , 2014, The Journal of clinical investigation.

[74]  T. B. Huber,et al.  Unraveling the role of podocyte turnover in glomerular aging and injury. , 2014, Journal of the American Society of Nephrology : JASN.

[75]  P. Boor,et al.  The regenerative potential of parietal epithelial cells in adult mice. , 2014, Journal of the American Society of Nephrology : JASN.

[76]  V. D’Agati,et al.  Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. , 2014, The Journal of clinical investigation.

[77]  S. Ishibe,et al.  Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance. , 2014, The Journal of clinical investigation.

[78]  B. Smeets,et al.  The emergence of the glomerular parietal epithelial cell , 2014, Nature Reviews Nephrology.

[79]  M. Takagi,et al.  Notch2 activation ameliorates nephrosis , 2014, Nature Communications.

[80]  Craig W Lindsley,et al.  Inhibition of the TRPC5 ion channel protects the kidney filter. , 2013, The Journal of clinical investigation.

[81]  N. Perico,et al.  Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. , 2013, The American journal of pathology.

[82]  N. Perico,et al.  Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. , 2013, The American journal of pathology.

[83]  D. Salant,et al.  Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis , 2013, Kidney international.

[84]  G. Remuzzi,et al.  Mechanisms and treatment of CKD. , 2012, Journal of the American Society of Nephrology : JASN.

[85]  Sara Conti,et al.  Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. , 2012, American journal of physiology. Renal physiology.

[86]  B. Haraldsson,et al.  The glomerular endothelium: new insights on function and structure , 2012, Current opinion in nephrology and hypertension.

[87]  Avi Ma’ayan,et al.  Krüppel-like Factor 15 (KLF15) Is a Key Regulator of Podocyte Differentiation* , 2012, The Journal of Biological Chemistry.

[88]  T. Reinheckel,et al.  CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. , 2011, The Journal of clinical investigation.

[89]  Lei Zhu,et al.  Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. , 2011, Journal of the American Society of Nephrology : JASN.

[90]  G. Remuzzi,et al.  Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. , 2011, The American journal of pathology.

[91]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[92]  L. Guarente Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. , 2011, The New England journal of medicine.

[93]  A. Rozkalne,et al.  Antagonistic Regulation of Actin Dynamics and Cell Motility by TRPC5 and TRPC6 Channels , 2010, Science Signaling.

[94]  S. Dryer,et al.  TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology. , 2010, American journal of physiology. Renal physiology.

[95]  A. Fogo,et al.  The glomerulus--a view from the inside--the endothelial cell. , 2010, The international journal of biochemistry & cell biology.

[96]  M. Carini,et al.  Notch Activation Differentially Regulates Renal Progenitors Proliferation and Differentiation Toward the Podocyte Lineage in Glomerular Disorders , 2010, Stem cells.

[97]  G. Remuzzi,et al.  Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[98]  R. Iyengar,et al.  Reduction of Stat3 activity attenuates HIV-induced kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[99]  Trixie Wagner,et al.  Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. , 2008, Journal of medicinal chemistry.

[100]  G. Remuzzi,et al.  Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. , 2008, Journal of the American Society of Nephrology : JASN.

[101]  Y. Sado,et al.  Podocytes contribute to the formation of glomerular crescents. , 2008, Journal of the American Society of Nephrology : JASN.

[102]  K. Suszták,et al.  The Notch pathway in podocytes plays a role in the development of glomerular disease , 2008, Nature Medicine.

[103]  P. Carmeliet,et al.  Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.

[104]  H. Kurihara,et al.  Actin filament organization of foot processes in vertebrate glomerular podocytes , 2007, Cell and Tissue Research.

[105]  M. Rastaldi,et al.  Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[106]  J. He,et al.  Animal models of HIV-associated nephropathy , 2006, Current opinion in nephrology and hypertension.

[107]  G. Remuzzi,et al.  ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. , 2006, Kidney international.

[108]  G. Remuzzi,et al.  Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. , 2006, The American journal of pathology.

[109]  M. Pericak-Vance,et al.  A Mutation in the TRPC6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis , 2005, Science.

[110]  G. Remuzzi,et al.  Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. , 2004, Seminars in nephrology.

[111]  M. Le Hir,et al.  J Am Soc Nephrol 15: 61–67, 2004 Podocytes Populate Cellular Crescents in a Murine Model of Inflammatory Glomerulonephritis , 2003 .

[112]  T. Hostetter Hyperfiltration and glomerulosclerosis. , 2003, Seminars in nephrology.

[113]  A. Fogo Animal models of FSGS: lessons for pathogenesis and treatment. , 2003, Seminars in nephrology.

[114]  W. Kriz Podocyte is the major culprit accounting for the progression of chronic renal disease , 2002, Microscopy research and technique.

[115]  Y. H. Kim,et al.  Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. , 2001, Kidney international.

[116]  R. Kalluri,et al.  Aminopeptidase A: a nephritogenic target antigen of nephrotoxic serum. , 2001, Kidney international.

[117]  Y. Wang,et al.  Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. , 2000, Kidney international.

[118]  M. Nagata,et al.  Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. , 2000, Kidney international.

[119]  K. Tryggvason,et al.  Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. , 1999, Journal of the American Society of Nephrology : JASN.

[120]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[121]  M. Karnovsky,et al.  Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. , 1986, The American journal of pathology.

[122]  G. Remuzzi,et al.  Adriamycin-induced glomerulosclerosis in the rat. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[123]  J. Coresh,et al.  A tripartite complex of suPAR, APOL1 risk variants and alpha(v)beta(3) integrin on podocytes mediates chronic kidney disease , 2022 .